enables it to pursue its efforts to develop a practical, effective
manufacturing platform to address the increasing demand for
high-volume protein based therapeutics as well as develop
novel therapeutics. This three-pronged business strategy
encompasses the following:
- Production of Generic Biologicals – Development and
manufacture of proven products for established and
growing markets. TranXenoGen’s initial focus is to
use its technology, which is under development, for the
production of Insulin and Human Serum Albumin.
- Proprietary Novel Products – Development and
manufacture of TranXenoGen’s proprietary novel
therapeutic proteins. The first of these is
TranXenoGen’s anti-cancer product, ANUP.
- Contract Partnerships – Development and manufacture
of high-volume novel therapeutics such as monoclonal
antibodies for strategic partners.
NEWS CENTER I CAREERS I CONTACT US I DIRECTIONS
TRANXENOGEN, INC. • PO BOX 21 • NORTHBORO, MA. 01532 • 508 842 5036
© COPYRIGHT TRANXENOGEN, INC. 2002